PsA: Ixekizumab more effective than adalimumab irrespective of concomitant psoriasis severityNovember 30, 2021Psoriatic Arthritis
Guselkumab shows long-term safety and efficacy in biologic-naive patients with PsANovember 30, 2021Psoriatic Arthritis
Swollen joints better predict ultrasound-defined inflammation in PsA than tender jointsNovember 30, 2021Psoriatic Arthritis
Risk for serious infection lower in patients with PsA vs. RA treated with TNF inhibitorsNovember 30, 2021Psoriatic Arthritis
PsA: Long-term benefits of upadacitinib in patients with inadequate response to biologicsNovember 30, 2021Psoriatic Arthritis
Dermatology NewsSerious infection hospitalizations have declined in patients with PsANovember 19, 2021Psoriatic Arthritis
Dermatology NewsTofacitinib postmarketing trial data shed light on JAK inhibitor risksNovember 16, 2021Psoriatic Arthritis
Dermatology NewsRisankizumab outperforms placebo at 6 months for psoriatic arthritisNovember 8, 2021Psoriatic Arthritis
Dermatology NewsHigher odds for preterm, C-section births seen in women with PsAOctober 28, 2021Psoriatic Arthritis
Effect of background methotrexate dose on tofacitinib efficacy in patients with PsAOctober 24, 2021Psoriatic Arthritis
Predictors and risk factors for PsA transition in patients with psoriasisOctober 24, 2021Psoriatic Arthritis
Itch relief major contributor for tofacitinib-mediated–improved QoL in PsAOctober 24, 2021Psoriatic Arthritis
PsA: Long-term apremilast offers clinical benefits in ACR20 nonrespondersOctober 24, 2021Psoriatic Arthritis
Psoriasis patients with more severe disease at higher risk of developing PsAOctober 24, 2021Psoriatic Arthritis
